Tuberculin skin test and Quantiferon TB Gold in Romanian BCG vaccinated, immunosuppressed patients with moderate-to-severe Crohn’s disease: a comparison with a Hungarian cohort

Preda, Carmen Monica; Fulger, Larisa Elena; Gheorghe, Cristian; Gheorghe, Liana; Manuc, Mircea; Negreanu, Lucian; Meianu, Corina; Slavulete, Bogdan Ionut; Diculescu, Mircea

doi:10.15403/jgld.2014.1121.252.tbg

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inclusion of abstracts and in 1 case a letter to the editor is another potential limitation. However, leaving out data from Preda et al [ 18 ] letter did not change results and overall concordance (0.847; 95% CI, 0.81–0.88) was similar, mainly due to small size of this cohort of patients. The inclusion of abstracts that have not been fully published could not be avoided, as there is a lack of sufficient data to generate a meta-analysis using only published randomized controlled trials.…”

Section: Discussionmentioning

confidence: 62%

“…Two authors responded and supplemented all missing data and clarifications needed for inclusion [ 11 , 12 ]. A total of 16 articles were finally included in our final analysis (5 conference abstracts [ 13 - 17 ], 1 correspondence letter [ 18 ], 10 full-text articles [ 11 , 12 , 19 - 26 ]). All eligible studies examined by Shahidi et al [ 7 ] were similarly reviewed prior to inclusion in the final 16 analyzed studies.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease

et al. 2020

View full text Add to dashboard Cite

Background/Aims: Latent tuberculosis screening is mandatory prior to initiating anti-tumor necrosis factor (anti-TNF) medications. Guidelines recommend interferon-gamma release assays (IGRA) as first line screening method for the general population. Studies provided conflicting evidence on IGRA and tuberculin skin test (TST) performance in inflammatory bowel disease (IBD) patients. We assessed test concordance and the effects of immunosuppression on their performance in IBD patients.Methods: We searched MEDLINE, Embase and Cochrane databases (2011–2018) for studies testing TST and IGRA in IBD. Primary outcome was TST and IGRA concordance. Secondary outcomes were effects of immunosuppressive therapy on performance. Immunosuppression defined as either steroids, thiopurine, methotrexate or cyclosporine use. We used the pooled random effects model to adjust for heterogeneity analyzed using (I2–Q statistics). We compared the fixed model to exclude smaller study effects.Results: Sixteen studies (2,488 patients) were included. Pooled TST and IGRA concordance was 85% (95% confidence interval [CI], 81%–88%; P=0.01). Effects of immunosuppression were reported in 8 studies (814 patients). The odds ratio of testing positive by IGRA decreased to 0.57 if immunosuppressed (95% CI, 0.31–1.03; P=0.06). The odds ratio of testing positive by TST if immunosuppressed was 1.14 (95% CI, 0.61–2.12; P=0.69). The fixed model yielded similar results, however the negative effect of immunosuppression on IGRA reached statistical significance (P=0.01).Conclusions: While concordance was 85% between TST and IGRA, the performance of IGRA seems to be negatively affected by immunosuppression. Given the importance of detecting latent tuberculosis prior to anti-TNF initiation, further randomized controlled trials comparing the performance of TST and IGRA in IBD patients are needed.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Resultsmentioning

confidence: 99%

Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease

et al. 2020

View full text Add to dashboard Cite

show abstract

Interferon-gamma assay and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease

Mungmunpuntipantip¹,

Wiwanitkit

2021

The Egyptian Journal of Chest Diseases and Tuberculosis

View full text Add to dashboard Cite

Background Latent tuberculosis is an important clinical problem. This problem might be significant in some specific groups of patients. The screening for latent tuberculosis is recommended for management of those patients at risk. An important group to be screened is patients with inflammatory bowel disease. Materials and methods This work is a retrospective study. The summarization on the available data from published articles on the comparative study between interferon-gamma assay and tuberculin skin test for screening for latent tuberculosis in inflammatory bowel disease patients was done. The pooled detection rate was calculated for using interferon-gamma assay and tuberculin skin test in screening for latent tuberculosis in patients with inflammatory bowel disease. Results The pooled detection rates for using tuberculin skin test and interferon-gamma assay in screening for latent tuberculosis in patients with inflammatory bowel disease are equal to 11.67% (95% confidence interval=10.33–13.19%) and 14.64% (95% confidence interval=13.16–16.30%), respectively. Conclusion It can be shown that interferon-gamma assay has a better efficacy in detection of latent tuberculosis among the patients with inflammatory bowel disease.

show abstract

Tuberculin skin test and Quantiferon TB Gold in Romanian BCG vaccinated, immunosuppressed patients with moderate-to-severe Crohn’s disease: a comparison with a Hungarian cohort

Abstract: .

Cited by 2 publications

References 0 publications

Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease

Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease

Interferon-gamma assay and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease

Contact Info

Product

Resources

About